These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30387527)

  • 1. Reduced brain amyloid burden in elderly patients with narcolepsy type 1.
    Gabelle A; Jaussent I; Bouallègue FB; Lehmann S; Lopez R; Barateau L; Grasselli C; Pesenti C; de Verbizier D; Béziat S; Mariano-Goulart D; Carlander B; Dauvilliers Y; ;
    Ann Neurol; 2019 Jan; 85(1):74-83. PubMed ID: 30387527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.
    Landau SM; Fero A; Baker SL; Koeppe R; Mintun M; Chen K; Reiman EM; Jagust WJ
    J Nucl Med; 2015 Apr; 56(4):567-74. PubMed ID: 25745095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
    Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
    J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse.
    Alcolea D; Pegueroles J; Muñoz L; Camacho V; López-Mora D; Fernández-León A; Le Bastard N; Huyck E; Nadal A; Olmedo V; Sampedro F; Montal V; Vilaplana E; Clarimón J; Blesa R; Fortea J; Lleó A
    Ann Clin Transl Neurol; 2019 Sep; 6(9):1815-1824. PubMed ID: 31464088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment.
    Wu L; Rowley J; Mohades S; Leuzy A; Dauar MT; Shin M; Fonov V; Jia J; Gauthier S; Rosa-Neto P;
    PLoS One; 2012; 7(10):e47905. PubMed ID: 23112868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation Between Brain 18F-AV45 and 18F-FDG PET Distribution Characteristics and Cognitive Function in Patients with Mild and Moderate Alzheimer's Disease.
    Jing J; Zhang F; Zhao L; Xie J; Chen J; Zhong R; Zhang Y; Dong C
    J Alzheimers Dis; 2021; 79(3):1317-1325. PubMed ID: 33427748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
    Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebellar Amyloid-β Plaques: How Frequent Are They, and Do They Influence 18F-Florbetaben SUV Ratios?
    Catafau AM; Bullich S; Seibyl JP; Barthel H; Ghetti B; Leverenz J; Ironside JW; Schulz-Schaeffer WJ; Hoffmann A; Sabri O
    J Nucl Med; 2016 Nov; 57(11):1740-1745. PubMed ID: 27363836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden.
    Blautzik J; Brendel M; Sauerbeck J; Kotz S; Scheiwein F; Bartenstein P; Seibyl J; Rominger A;
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1364-1374. PubMed ID: 28326436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between amyloid levels, glucose metabolism, morphologic changes in the brain and clinical status of patients with Alzheimer's disease.
    Thientunyakit T; Sethanandha C; Muangpaisan W; Chawalparit O; Arunrungvichian K; Siriprapa T; Vichianin Y; Kamal S; Suppasilp C; Thongpraparn T; Chanachai R; Gelovani JG
    Ann Nucl Med; 2020 May; 34(5):337-348. PubMed ID: 32152925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
    Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
    Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction.
    Brendel M; Högenauer M; Delker A; Sauerbeck J; Bartenstein P; Seibyl J; Rominger A;
    Neuroimage; 2015 Mar; 108():450-9. PubMed ID: 25482269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
    Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
    Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-β Positron Emission Tomography.
    Beyer L; Brendel M; Scheiwein F; Sauerbeck J; Hosakawa C; Alberts I; Shi K; Bartenstein P; Ishii K; Seibyl J; Cumming P; Rominger A;
    J Alzheimers Dis; 2020; 74(1):101-112. PubMed ID: 31985461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.
    Palmqvist S; Mattsson N; Hansson O;
    Brain; 2016 Apr; 139(Pt 4):1226-36. PubMed ID: 26936941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Precuneus - A Witness for Excessive Aβ Gathering in Alzheimer's Disease Pathology.
    Aghakhanyan G; Vergallo A; Gennaro M; Mazzarri S; Guidoccio F; Radicchi C; Ceravolo R; Tognoni G; Bonuccelli U; Volterrani D
    Neurodegener Dis; 2018; 18(5-6):302-309. PubMed ID: 30814473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.